Brought to you by 
ProFibrix brings in $11mm though Series B round
03 May 2011
Executive Summary
ProFibrix (hemostasis and regenerative medicine) raised $11mm through its Series B round. New investor Gilde Healthcare Partners, which takes a seat on the company's supervisory board, was joined by returning backer Index Ventures. ProFibrix will use some of the proceeds to continue developing its lead product Fibrocaps, a powder mixture of fibrinogen and thrombin used as a topical sealant to stop bleeding during and after surgery.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
-
Surgical Equipment & Devices
- Surgical Sealants
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProFibrix brings in $11mm though Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice